Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

STRATA Skin Sciences (SSKN) Net Income towards Common Stockholders (2016 - 2025)

STRATA Skin Sciences (SSKN) has disclosed Net Income towards Common Stockholders for 14 consecutive years, with $70000.0 as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 101.48% to $70000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.2 million through Dec 2025, up 43.8% year-over-year, with the annual reading at -$6.3 million for FY2025, 38.19% up from the prior year.
  • Net Income towards Common Stockholders hit $70000.0 in Q4 2025 for STRATA Skin Sciences, up from -$1.6 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $70000.0 in Q4 2025 to a low of -$4.7 million in Q4 2024.
  • Historically, Net Income towards Common Stockholders has averaged -$1.9 million across 5 years, with a median of -$2.1 million in 2024.
  • Biggest five-year swings in Net Income towards Common Stockholders: crashed 3138.33% in 2023 and later soared 101.48% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$849000.0 in 2021, then soared by 85.87% to -$120000.0 in 2022, then plummeted by 3138.33% to -$3.9 million in 2023, then fell by 21.59% to -$4.7 million in 2024, then surged by 101.48% to $70000.0 in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for SSKN at $70000.0 in Q4 2025, -$1.6 million in Q3 2025, and -$2.6 million in Q2 2025.